XERSHealthcareSmall-Cap
Xeris Biopharma Holdings, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Xeris Biopharma Holdings, Inc. (XERS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are XERS insiders buying or selling?
Xeris Biopharma Holdings, Inc. insiders reported 18 open-market buys ($1.2M) and 27 sells ($5.9M) across 45 Form 4 filings — a net selling position of $4.7M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 7, 2026)
Total Form 4 filings
45
SEC EDGAR
Insider filers
13
Insider buys (18)
$1.2M
Insider sells (27)
$5.9M
Insider sentiment
Net sellingNet insider flow of $4.7M in net selling.
Recent XERS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Steven Pieper | Chief Financial Officer | Sale | 45.0K | $8.52 | $383.2K |
| Jul 2, 2026 | Kevin Mcculloch | President and Chief Operating Officer | Sale | 90.0K | $8.03 | $722.5K |
| Jul 2, 2026 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $8.03 | $133.9K |
| Jun 5, 2026 | Marla Persky | Director | Sale | 15.5K | $5.90 | $91.4K |
| Jun 5, 2026 | Dawn Halkuff | Director | Sale | 20.0K | $6.09 | $121.9K |
| Jun 5, 2026 | Barbara-Jean Anne Bormann-Kennedy | Director | Sale | 16.0K | $6.09 | $97.5K |
| Jun 5, 2026 | John Johnson | Director | Sale | 15.0K | $6.09 | $91.4K |
| Jun 2, 2026 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $6.06 | $101.0K |
| May 1, 2026 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $6.23 | $103.8K |
| Apr 3, 2026 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $5.99 | $99.9K |
| Apr 1, 2026 | James Aloysius Brady | Director | Sale | 10.8K | $5.54 | $60.0K |
| Mar 4, 2026 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $6.25 | $104.1K |
| Feb 2, 2026 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $7.45 | $124.1K |
| Jan 9, 2026 | Kevin Mcculloch | President and Chief Operating Officer | Sale | 15.0K | $8.00 | $120.0K |
| Jan 6, 2026 | John Patrick Shannon Jr | Chief Executive Officer and Director | Sale | 24.9K | $7.08 | $176.3K |
| Jan 5, 2026 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $7.43 | $123.8K |
| Dec 19, 2025 | John Johnson | Director | Sale | 135.4K | $7.22 | $977.0K |
| Dec 15, 2025 | Barbara-Jean Anne Bormann-Kennedy | Director | Sale | 15.0K | $7.09 | $106.4K |
| Dec 2, 2025 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $7.01 | $116.8K |
| Nov 17, 2025 | John Patrick Shannon Jr | Chief Executive Officer and Director | Sale | 23.2K | $7.46 | $173.4K |
| Nov 13, 2025 | Beth Hecht | Chief Legal Officer and Corporate Secretary | Sale | 16.7K | $7.40 | $123.3K |
| Sep 12, 2025 | Marla Persky | Director | Sale | 15.5K | $7.72 | $119.6K |
| Aug 29, 2025 | Jeffrey W Sherman | Director | Sale | 42.2K | $7.92 | $334.5K |
| Aug 15, 2025 | John Johnson | Director | Sale | 107.5K | $7.32 | $786.5K |
| Aug 13, 2025 | Dawn Halkuff | Director | Sale | 42.5K | $7.28 | $309.2K |
Showing the 25 most recent of 45 Form 4 filings for Xeris Biopharma Holdings, Inc..
Most active XERS insiders
- Beth Hecht10 filings
- John P. Schmid5 filings
- Paul R Edick5 filings
- John Patrick Shannon Jr4 filings
- Dawn Halkuff3 filings
Ask anything about XERS insider activity
Use Trabud's AI agent to query Xeris Biopharma Holdings, Inc.'s Form 4 history in plain English — "Show me XERS CEO purchases this year" or compare it against any other ticker.
Open the AI agentXERS insider trading FAQ
Are Xeris Biopharma Holdings, Inc. insiders buying or selling?
Across 45 SEC Form 4 filings, Xeris Biopharma Holdings, Inc. (XERS) insiders reported 18 open-market purchases totaling $1.2M and 27 sales totaling $5.9M. That is a net selling position of $4.7M.
How many insiders trade XERS stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Xeris Biopharma Holdings, Inc.. The most recent filing was accepted on Jul 7, 2026.
Where does Trabud get XERS insider trading data?
All XERS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.